Low enzyme production, most often referring to insufficient output of digestive enzymes from the pancreas, leads to poor breakdown and absorption of nutrients from food. The medical term for this is exocrine pancreatic insufficiency (EPI), and it affects the majority of people with chronic pancreatitis, a large share of those with cystic fibrosis, and smaller but meaningful numbers of people with diabetes, advanced age, or a history of gastrointestinal surgery. The condition is underdiagnosed partly because its hallmark symptoms, like bloating, loose stools, and unexplained weight loss, overlap with so many other gut complaints. Understanding what drives it, what to watch for, and what actually helps can make a real difference in quality of life.
Why Enzyme Output Drops
Your pancreas produces enzymes (lipase for fat, protease for protein, amylase for starch) and adjusts its output depending on what you eat. In a healthy system, eating a fatty meal triggers a surge of lipase; eating a protein-heavy meal triggers more protease. That adaptive response is tightly regulated, and when it breaks down, the consequences ripple across digestion and nutrition.
The most common cause of clinically significant low enzyme production is chronic pancreatitis, the slow, progressive inflammation and scarring of pancreatic tissue. As the organ sustains damage over years, it loses its ability to synthesize and release enzymes in response to meals. In an unselected group of chronic pancreatitis patients, pancreatic exocrine function is reduced by roughly 50 to 80 percent compared to healthy people, and the vast majority show at least some degree of insufficiency.1Pancreapedia. Diagnosis of pancreatic exocrine insufficiency in chronic pancreatitis What makes this tricky is that obvious malabsorption, the kind you can see in the form of oily stools and rapid weight loss, only shows up once enzyme secretion has dropped by more than 90 percent. That means a person can lose a huge share of their pancreatic function before symptoms become severe enough to prompt a diagnosis.
Cystic fibrosis (CF) is another major driver, and it begins damaging the pancreas far earlier in life. The underlying genetic mutation disrupts a protein channel on the surface of cells lining the digestive tract, which impairs the flow of chloride, water, and bicarbonate into the pancreatic ducts. Secretions become thick and sticky, blocking the ducts and eventually destroying the tissue that produces enzymes.2Digestive and Liver Disease. Digestive system dysfunction in cystic fibrosis: Challenges for nutrition therapy Research in animal models has confirmed that the loss of this channel function alone is enough to cause severe pancreatic destruction, underscoring how central it is to maintaining a working exocrine pancreas.3PubMed Central. Protein sorting and proteostasis mechanisms in CFTR-related exocrine pancreas dysfunction: A systematic narrative review Most people with CF develop pancreatic insufficiency and need lifelong enzyme supplementation.
Aging also takes a quiet toll. Studies of pancreatic secretion across age groups have found that enzyme concentration and total enzyme output decline in a roughly linear fashion starting around the third decade of life. Water and bicarbonate secretion drop too, though enzyme output tends to fall first.4PubMed. Changes in pancreatic exocrine secretion with age For most older adults, this decline is not severe enough to require treatment, but in some individuals it can tip into genuine insufficiency, especially when combined with other factors like poor nutrition or medications that affect digestion.5PubMed. Impact of aging on the digestive system related to protein digestion in vivo
Diabetes, particularly long-standing type 1 or type 2, is an underappreciated cause. Insulin has a trophic effect on the pancreas, meaning it helps maintain the health of enzyme-producing cells. When insulin is deficient or when chronic high blood sugar exerts toxic effects, the pancreas can undergo inflammation, fibrosis, fat infiltration, and atrophy, all of which reduce its enzyme-making capacity.6Herald of Pancreatic Club. Exocrine pancreatic insufficiency in diabetes This connection is often missed because clinicians focus on the endocrine side of diabetes (blood sugar control) and overlook the exocrine side (digestion).
Gastric surgery, including partial or total removal of the stomach, can also cause low enzyme activity even when the pancreas itself is intact. The rearranged anatomy disrupts the normal timing between food entering the small intestine and the release of pancreatic enzymes, creating a mismatch that undermines digestion. This asynchrony, combined with reduced signaling to the pancreas from the shortened digestive tract, is a significant contributor to malnutrition after surgery.7ScienceDirect. Pancreatic enzyme replacement therapy after gastric resection: An update
Signs That Point to Low Enzyme Production
The symptoms of EPI develop because food is not being broken down properly, and the downstream effects touch almost every system in the body. The hallmark sign is steatorrhea: pale, bulky, greasy stools that float and are difficult to flush. This happens because undigested fat passes through to the colon. But steatorrhea only becomes obvious at the extreme end of enzyme loss, so milder cases often present with symptoms that are less specific and easier to dismiss.
Bloating and excessive gas are common early complaints. When fats, proteins, or carbohydrates are not fully digested in the small intestine, they pass into the colon, where gut bacteria ferment them. This fermentation produces gas as a by-product, and a healthy gut already generates a substantial volume of gas each day from normal bacterial metabolism of dietary residues.8Journal of Functional Foods. Intestinal gas production by the gut microbiota: A review When undigested food arrives in the colon in larger-than-normal amounts, that gas production increases, leading to uncomfortable distension, cramping, and flatulence.
Unintended weight loss and muscle wasting develop as malabsorption worsens. If you are not absorbing enough calories and protein from your food, your body begins breaking down its own reserves. People with EPI often describe eating normal or even large meals yet still losing weight, which is a frustrating and alarming experience.
Fat-soluble vitamin deficiencies are among the more serious long-term consequences. Because fat is poorly absorbed, so are the vitamins that dissolve in it: A, D, E, and K. Vitamin D deficiency is especially concerning because it disrupts bone metabolism and can reduce bone mineral density over time.9Journal of the Pancreas. Altered Bone Metabolism and Bone Density in Patients with Chronic Pancreatitis and Pancreatic Exocrine Insufficiency People with chronic pancreatitis and EPI are at elevated risk for osteoporosis and fractures, a complication that rarely gets discussed in the context of digestive disease. Vitamin A deficiency can affect vision and immunity, while vitamin K deficiency can impair blood clotting.
Other signs include diarrhea (though some people experience constipation instead), fatigue that does not improve with rest, and a general sense that food “sits” in the stomach for too long. Because these symptoms overlap heavily with irritable bowel syndrome, celiac disease, and food intolerances, EPI can go years without being identified.
How Doctors Test for It
The most widely used screening test for low enzyme production is a fecal elastase-1 (FE-1) measurement. Elastase-1 is an enzyme produced by the pancreas that passes through the gut without being broken down, so its concentration in stool reflects how much the pancreas is actually secreting. A level below 200 micrograms per gram of stool is considered abnormal, and levels below 100 suggest severe insufficiency.
The test performs well for moderate to severe cases. In studies of people with cystic fibrosis, FE-1 at the 200 microgram cutoff reached 100 percent sensitivity for moderate to severe EPI and showed specificity above 96 percent.10PubMed Central. Utility of Fecal Elastase‐1 in Estimating Exocrine Pancreatic Function in Cystic Fibrosis: A Scoping Review The weakness is in mild disease, where sensitivity dropped to as low as 25 percent in one evaluation. In practical terms, a very low FE-1 result is highly informative, but a normal or borderline result does not necessarily rule out mild insufficiency.
For cases where the fecal elastase test is ambiguous, breath tests using carbon-13-labeled substrates offer another approach. These tests work by having the patient swallow a labeled fat (typically a mixed triglyceride), which can only be digested if pancreatic lipase is present and active. The labeled carbon then appears in exhaled breath, and the amount detected reflects how well the enzymes are working. The mixed triglyceride breath test has been validated against more invasive reference methods for diagnosing EPI and for evaluating whether enzyme replacement therapy is working.11PubMed. Breath testing for the diagnosis of pancreatic disease12Pancreas. 13 C Breath Tests for the Assessment of Exocrine Pancreatic Function
Direct pancreatic function testing, where a tube is placed into the duodenum and secretions are collected after hormonal stimulation, remains the gold standard but is invasive, time-consuming, and only available at specialized centers. In practice, most people are diagnosed through a combination of fecal elastase, symptoms, and response to a trial of enzyme replacement therapy. If symptoms improve after starting enzymes, that itself serves as confirmation.
Pancreatic Enzyme Replacement Therapy
The cornerstone treatment for low enzyme production is pancreatic enzyme replacement therapy, or PERT. These are capsules containing porcine-derived lipase, protease, and amylase in enteric-coated microspheres designed to survive stomach acid and release their contents in the small intestine, where digestion happens.
Recommended starting doses are at least 30,000 to 40,000 international units (IU) of lipase with each main meal and 15,000 to 20,000 IU with snacks.13PubMed Central. Pancreatic Enzyme Replacement Therapy: A Concise Review An important practical point that many people miss: the capsules should be taken in divided doses throughout the meal, not swallowed all at once before eating. Splitting the dose, for example half at the start and half midway through, helps ensure the enzymes mix with food as it moves into the duodenum.
Not all enzyme products are equally effective, even when their labeled lipase content is similar. Laboratory testing comparing products available in Europe and Canada found significant differences in how they perform. Creon, one of the most widely prescribed brands, released minimal lipase in simulated stomach conditions (less than 4 percent), which is exactly what you want since premature release means the enzyme gets destroyed by acid before it can do its job. Under simulated small intestine conditions, Creon reached about 87 percent lipase activity. Several other products showed much lower activity in the same conditions, with some achieving only 26 to 44 percent after 30 minutes.14PubMed Central. In-Vitro Comparison of Physical Characteristics, Enzyme Content, and Release Kinetics of Pancreatic Enzyme Preparations Available in Europe and Canada These differences matter clinically: an enzyme capsule that releases its contents too early in the stomach or too slowly in the intestine will not improve digestion as effectively.
If the initial dose does not control symptoms, the next step is typically to increase the dose rather than switch products. Some clinicians also consider adding a proton pump inhibitor (PPI) to reduce stomach acid, under the logic that a less acidic duodenum would help lipase survive longer. The evidence for this, however, is weaker than expected. A randomized crossover pilot trial in people with cystic fibrosis and EPI who were already on PERT found that adding a PPI did not improve fat absorption and may have actually impaired it, based on breath test results that are considered a direct measure of fatty acid absorption.15PubMed Central. Proton-Pump Inhibitors and Fat Absorption in Cystic Fibrosis and Pancreatic Insufficiency: A Randomized Crossover Pilot Trial That finding was unexpected and came from a small trial, so it is not definitive, but it does suggest that routinely adding acid suppression to enzyme therapy is not as straightforward as it sounds.
Dietary Adjustments That Help
Enzyme capsules do much of the heavy lifting, but dietary choices play a supporting role. One approach that has stood up over decades is the use of medium-chain triglycerides (MCT oil) as a partial replacement for regular dietary fat. Unlike the long-chain fats found in most foods, medium-chain fats are absorbed more directly and do not rely as heavily on pancreatic lipase for digestion. Long-term follow-up of patients with severe fat malabsorption who substituted dietary fat with MCT oil showed that the strategy was safe and effective over more than 30 years, with no signs of liver damage or other serious side effects from continuous use.16PubMed Central. Thirty-Three Years Follow-Up of a Greek Family with Abetalipoproteinemia: Absence of Liver Damage on Long-Term Medium Chain Triglycerides Supplementation While that study was in a rare genetic condition rather than EPI specifically, the principle of using MCT oil to bypass the need for lipase applies across conditions where fat absorption is compromised.
Food preparation also matters more than most people realize. Many plant foods, particularly pulses like beans, lentils, and chickpeas, naturally contain enzyme inhibitors that interfere with protease and amylase activity. Soaking these foods before cooking markedly reduces those inhibitors, and cooking the pre-soaked seeds is even more effective, with reductions of roughly 79 to 100 percent for all pulses tested.17PubMed Central. Changes in levels of enzyme inhibitors during soaking and cooking for pulses available in Canada For someone whose pancreatic enzyme output is already low, eating poorly prepared legumes adds an extra obstacle to digestion. Proper soaking and thorough cooking removes most of that barrier.
Smaller, more frequent meals tend to be better tolerated than large ones. A large meal overwhelms the limited enzyme supply, whereas spreading the same food across four to six smaller meals gives the available enzymes a better chance of keeping up. This also reduces the bloating and discomfort that often follow big meals in people with EPI. Many clinicians also recommend supplementing fat-soluble vitamins (A, D, E, and K) separately, since even with enzyme therapy, absorption of these vitamins may not fully normalize.
Why EPI Gets Missed So Often
One of the more frustrating aspects of low enzyme production is how long it can take to diagnose. Part of the problem is the 90 percent threshold: because the pancreas has such enormous reserve capacity, a person can lose the majority of their enzyme output before the textbook symptoms of steatorrhea and dramatic weight loss appear.1Pancreapedia. Diagnosis of pancreatic exocrine insufficiency in chronic pancreatitis In the milder stages, the symptoms are vague enough to be attributed to irritable bowel syndrome, lactose intolerance, or simply “a sensitive stomach.”
The connection between diabetes and EPI adds another layer of missed diagnoses. Many people with long-standing diabetes experience bloating, diarrhea, or unexplained nutritional deficiencies that get chalked up to diabetic neuropathy affecting gut motility, when reduced enzyme production may be a contributing or primary factor. Screening for EPI with a simple fecal elastase test is inexpensive, but it is not routinely done in diabetes clinics.
Post-surgical patients face a similar blind spot. After stomach surgery, digestive complaints are expected and often treated symptomatically with dietary advice and antidiarrheal medications. The possibility that the anatomy itself is preventing enzymes from meeting food at the right time tends to get less attention than it deserves. PERT can substantially improve nutritional outcomes in these patients, but only if the diagnosis is considered in the first place.
When the Cause Is Not the Pancreas
Not all low enzyme activity traces back to the pancreas itself. The small intestine produces its own set of enzymes, including lactase (for dairy sugar), sucrase (for table sugar), and peptidases (for protein fragments). These brush-border enzymes can be reduced by conditions that damage the intestinal lining, such as celiac disease, Crohn’s disease, infections, or radiation therapy. Lactose intolerance is the most familiar example: the enzyme lactase declines in the majority of the world’s adult population as a normal part of post-weaning biology, and the resulting inability to break down milk sugar causes gas, bloating, and diarrhea that mimic pancreatic insufficiency.
The distinction matters because the treatment is different. Pancreatic enzyme capsules will not help someone whose problem is brush-border enzyme deficiency, and lactase supplements will not help someone whose pancreas is failing. When symptoms overlap, sorting out which enzymes are actually deficient requires targeted testing and a careful look at the full clinical picture. Some people have both problems simultaneously, particularly those with cystic fibrosis or advanced chronic pancreatitis who have also developed secondary intestinal damage from chronic malabsorption and inflammation.
Environmental and Dietary Chemicals That Interfere with Enzyme Adaptation
Beyond disease and aging, external exposures can disrupt the pancreas’s normal ability to match enzyme output to diet. Animal research has shown that certain environmental chemicals, including organochlorine pesticides and agricultural fungicides, impair the adaptive response of pancreatic enzymes. In control animals, protein intake triggered an appropriate rise in protease activity, and fat intake triggered a rise in lipase. But animals exposed to these chemicals lost that adaptive flexibility.18Academia Open. Alterations in the Adaptation of Pancreatic Enzymes to Food Quality under the Influence of Hexachlorocyclohexane and Tetramethylthiuram Disulfide The enzymes were still being produced, but the fine-tuning was gone.
This area of research is still in its early stages and mostly limited to animal models, so it would be premature to draw firm conclusions about human dietary exposures. Still, it raises an interesting question about whether chronic low-level exposure to certain chemicals contributes to the subclinical enzyme insufficiency that some people experience without an obvious underlying disease. For people who already have compromised pancreatic function, additional chemical insults could plausibly push them over the threshold into symptomatic territory. It is a thread worth watching as more data accumulate.